Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy

Background:Loss of HLA class I is important in ovarian cancer prognosis but its role as a prognostic indicator in relation to therapy remains unproven. We studied the prognostic potential of this antigen and its significance in relation to platinum therapy.Methods:A total of 157 primary ovarian cancers were assessed for HLA class I immunohistochemically and linked to a comprehensive database of clinicopathological variables, treatment details, and platinum sensitivity.Results:Tumours expressing high levels of HLA class I had significantly improved survival (P=0.044). There was a 19-month difference in the median overall survival between tumours with high and low antigen expression. HLA class I antigen expression, stage, and platinum sensitivity were independently predictive of prognosis on multivariate analysis. HLA class I antigen was shown to be expressed at higher levels in patients with good overall survival in platinum-resistant patients (P=0.042). HLA class I significantly correlated with overall survival on multivariate analyses (P=0.034).Conclusion:Low-level HLA class I expression is an independent prognostic indicator of poor clinical outcome in ovarian cancer. The survival advantage of patients with platinum-resistant tumours expressing high levels of HLA class I suggests that immunotherapy may be of use in these ovarian cancers resistant to standard chemotherapy.

• Publication year

  2009

• Venue

  British Journal of Cancer

• Publication date

  2009-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bjc.6605315PMID 19755991PMCID 2768455
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• Among platinum-resistant disease cases, higher HLA class I expression was associated with better overall survival.

  Confidence 0.92

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review
• HLA class I expression, stage, and platinum sensitivity were independent predictors of prognosis on multivariate analysis.

  Confidence 0.95

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review
• High HLA class I expression was associated with improved overall survival in the ovarian cancer cohort, with a 19-month median overall survival difference compared with low expression.

  Confidence 0.97

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review

• hla class i expression

  biomarker, protein expression

  The level of HLA class I antigen detected by immunohistochemistry in primary ovarian tumor samples.

  Aliases: HLA class I antigen expression, HLA class I antigen

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review
• multivariate analysis

  statistical method, analysis

  The statistical modeling approach used to test whether variables independently predicted prognosis.

  Aliases: multivariate analyses

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review
• ovarian cancer

  disease, cohort

  The primary ovarian cancer cohort analyzed for associations between antigen expression, treatment features, and survival.

  Aliases: ovarian cancers

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review
• overall survival

  outcome, survival endpoint

  The time-to-death clinical outcome used to assess prognosis in the patient cohort.

  Aliases: OS

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review
• platinum-resistant disease

  disease subgroup, treatment response

  The subgroup of ovarian cancers that did not respond well to first-line platinum chemotherapy.

  Aliases: platinum-resistant patients, platinum-resistant tumours

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review
• platinum sensitivity

  treatment response, clinical variable

  The tumor response category describing sensitivity or resistance to first-line platinum chemotherapy.

  Aliases: platinum-resistant, platinum resistance

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewjihoonc (k5vuy3tzcm) review

• Human leukocyte antigen-G and cancer immunoediting.

  2008cited by this paper
• HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma

  2008cited by this paper
• Human Leukocyte Antigen Class I Antigen Expression Is an Independent Prognostic Factor in Ovarian Cancer

  2007cited by this paper
• GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma.

  2006cited by this paper
• Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

  2006cited by this paper
• Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

  2006cited by this paper
• Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis

  2006cited by this paper
• Total loss of MHC class I is an independent indicator of good prognosis in breast cancer

  2005cited by this paper
• HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?

  2005cited by this paper
• HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.

  2005cited by this paper
• Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

  2004cited by this paper
• HLA-G and MIC expression in tumors and their role in anti-tumor immunity.

  2003cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective.

  2003cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Tapasin-the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum.

  2002cited by this paper
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

  2002cited by this paper
• MHC antigens and tumor escape from immune surveillance.

  2001cited by this paper
• Antigen-processing machinery breakdown and tumor growth.

  2000cited by this paper
• Clinical characteristics of clear cell carcinoma of the ovary

  2000cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.

  1999cited by this paper
• Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Natural history of HLA expression during tumour development.

  1993cited by this paper
• In search of the 'missing self': MHC molecules and NK cell recognition.

  1990cited by this paper
• Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

  1986influential reference
• Reproductive Biology and Endocrinology Open Access the Role of Hla-g in Human Pregnancy

  year unknowncited by this paper

• HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer.

  2025cites this paper
• Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome

  2025cites this paper
• Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

  2022cites this paper
• The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.

  2022cites this paper
• HLA allele-specific expression: Methods, disease associations, and relevance in hematopoietic stem cell transplantation

  2022cites this paper
• Guiding immunotherapy combinations: who gets what?

  2021cites this paper
• Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response

  2021cites this paper
• Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

  2021cites this paper
• A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients

  2020cites this paper
• Cancer Immunotherapy: Future Prospective with Wide Therapeutic Spectrum

  2020cites this paper
• Understanding heterogeneous tumor microenvironment in metastatic melanoma

  2019cites this paper
• Cten promotes Epithelial–Mesenchymal Transition (EMT) in colorectal cancer through stabilisation of Src

  2019cites this paper
• The Cten signalling pathway stabilises Src protein to promote Epithelial-Mesenchymal Transition (EMT) in colorectal cancer

  2018cites this paper
• REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION

  2018cites this paper
• Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer

  2018cites this paper
• Metal Drugs and the Anticancer Immune Response.

  2018cites this paper
• Caractérisation topologique d'interactions non-covalentes inter- et intramoléculaires

  2017cites this paper
• Chapter 61 – Ovarian Cancer

  2016cites this paper
• HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer

  2015cites this paper
• Immune EscapeMechanisms as aGuide for Cancer Immunotherapy

  2015cites this paper
• Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

  2014cites this paper
• HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas

  2014cites this paper
• Prognostic Impact of Human Leukocyte Antigen Class I Expression and Association of Platinum Resistance with Immunologic Profiles in Epithelial Ovarian Cancer

  2014cites this paper
• Beta-2-microglobulin gene transfer in hla class i deficient tumor cells using recombinant adenovirus

  2014cites this paper
• Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms

  2013cites this paper
• Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.

  2013cites this paper
• High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

  2012cites this paper
• Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells.

  2011cites this paper
• Tumor escape after immunotherapy: implication of hla class i expression in melanoma and bladder tumors

  2011cites this paper
• Molecular specificities of NK cell-mediated recognition of human tumor cells

  2010cites this paper